DE69510810D1 - Lamanin-ketten: diagnostische und therapeutische verwendung - Google Patents

Lamanin-ketten: diagnostische und therapeutische verwendung

Info

Publication number
DE69510810D1
DE69510810D1 DE69510810T DE69510810T DE69510810D1 DE 69510810 D1 DE69510810 D1 DE 69510810D1 DE 69510810 T DE69510810 T DE 69510810T DE 69510810 T DE69510810 T DE 69510810T DE 69510810 D1 DE69510810 D1 DE 69510810D1
Authority
DE
Germany
Prior art keywords
lamanine
diagnostic
chains
therapeutic use
laminin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69510810T
Other languages
English (en)
Other versions
DE69510810T2 (de
Inventor
Karl Tryggvason
Pekka Kallunki
Charles Pyke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRYGGVASON, KARL, STOCKHOLM, SE
Original Assignee
TRYGGVASON
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRYGGVASON filed Critical TRYGGVASON
Publication of DE69510810D1 publication Critical patent/DE69510810D1/de
Application granted granted Critical
Publication of DE69510810T2 publication Critical patent/DE69510810T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
DE69510810T 1994-10-04 1995-10-04 Lamanin-ketten: diagnostische und therapeutische verwendung Expired - Fee Related DE69510810T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/317,450 US5660982A (en) 1994-10-04 1994-10-04 Laminin chains: diagnostic uses
PCT/EP1995/003918 WO1996010646A1 (en) 1994-10-04 1995-10-04 Laminin chains: diagnostic and therapeutic use

Publications (2)

Publication Number Publication Date
DE69510810D1 true DE69510810D1 (de) 1999-08-19
DE69510810T2 DE69510810T2 (de) 1999-11-04

Family

ID=23233705

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69510810T Expired - Fee Related DE69510810T2 (de) 1994-10-04 1995-10-04 Lamanin-ketten: diagnostische und therapeutische verwendung

Country Status (9)

Country Link
US (4) US5660982A (de)
EP (1) EP0784703B1 (de)
AT (1) ATE182180T1 (de)
AU (1) AU699183B2 (de)
DE (1) DE69510810T2 (de)
DK (1) DK0784703T3 (de)
ES (1) ES2133813T3 (de)
GR (1) GR3031488T3 (de)
WO (1) WO1996010646A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0954328A4 (de) * 1996-06-05 2002-07-17 Gen Hospital Corp Laminin-5 und die Herstellung einer Basalmembranstruktur
US6208749B1 (en) * 1997-02-28 2001-03-27 Electro-Optical Sciences, Inc. Systems and methods for the multispectral imaging and characterization of skin tissue
WO1999019348A1 (en) * 1997-10-10 1999-04-22 The General Hospital Corporation Laminins and uses thereof
US6682911B1 (en) 1997-10-10 2004-01-27 The General Hospital Corporation Laminins and uses thereof
US6294356B1 (en) 1998-01-16 2001-09-25 Northwestern University Methods and materials for making and using laminin-5
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
AU4675300A (en) * 1999-04-30 2000-11-17 Biostatum, Inc. Recombinant laminin 5
US6703363B1 (en) 1999-04-30 2004-03-09 Biostratum, Inc. Recombinant laminin 5
WO2001093851A2 (en) * 2000-06-08 2001-12-13 Chiron Corporation Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3
AU2001296846B2 (en) * 2000-10-12 2007-07-05 University Of Rochester Compositions that inhibit proliferation of cancer cells
US8613907B2 (en) 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
US20040120959A1 (en) * 2001-01-08 2004-06-24 Karl Tryggvason Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
DE10130800B4 (de) 2001-06-22 2005-06-23 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
EP1424558A4 (de) * 2001-08-17 2004-12-15 Eisai Co Ltd Reagenz zum testen von laminin-5-antigen in einer biologischen probe und testverfahren
US6916618B2 (en) * 2002-01-24 2005-07-12 University Of Guelph Isolation of the lamin γ2 gene in horses and its use in diagnostic junctional epidermolysis bullosa
WO2004039401A2 (en) * 2002-10-29 2004-05-13 Sirpa Salo Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis
WO2005001079A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Soft tissue repair and regeneration using postpartum-derived cells
US20070065447A1 (en) * 2003-10-29 2007-03-22 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
CN103421760A (zh) 2003-11-19 2013-12-04 金克克国际有限公司 丝氨酸蛋白酶、编码丝氨酸酶的核酸以及包含它们的载体和宿主细胞
US7985569B2 (en) 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
EP1694839A2 (de) * 2003-12-12 2006-08-30 Novo Nordisk A/S Laminin-5-modulatoren und verwendungen davon
WO2005079508A2 (en) * 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
US20050220760A1 (en) * 2004-04-02 2005-10-06 Clemson University Novel immunotherapy
US20070014788A1 (en) * 2004-12-13 2007-01-18 Novo Nordisk A/S Laminin-5 modulators and uses thereof
CA2541037A1 (en) 2005-03-31 2006-09-30 Sherwood Services Ag Temperature regulating patient return electrode and return electrode monitoring system
US20100260764A1 (en) * 2007-08-29 2010-10-14 Marinkovich M Peter Compositions and methods for inhibiting squamous cell carcinoma
US7618801B2 (en) 2007-10-30 2009-11-17 Danison US Inc. Streptomyces protease
US8545845B2 (en) 2008-06-18 2013-10-01 Karl Tryggvason Antibodies against domains of laminin-332
US20140045196A1 (en) * 2012-08-13 2014-02-13 University Of Tokyo Methods of prognosis and diagnosis of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5152980A (en) * 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances

Also Published As

Publication number Publication date
EP0784703A1 (de) 1997-07-23
WO1996010646A1 (en) 1996-04-11
DK0784703T3 (da) 1999-11-29
GR3031488T3 (en) 2000-01-31
ES2133813T3 (es) 1999-09-16
DE69510810T2 (de) 1999-11-04
US20050048518A1 (en) 2005-03-03
AU699183B2 (en) 1998-11-26
US20030100529A1 (en) 2003-05-29
ATE182180T1 (de) 1999-07-15
EP0784703B1 (de) 1999-07-14
AU3745195A (en) 1996-04-26
US6143505A (en) 2000-11-07
US5660982A (en) 1997-08-26

Similar Documents

Publication Publication Date Title
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
FR2703693B1 (fr) Procédé rapide de détermination d'une séquence d'ADN et application au séquençage et au diagnostic.
ATE315654T1 (de) Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
ATE181422T1 (de) Verfahren zur diagnose von praeklampsie
DE820303T1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
DE60028544D1 (de) Prostata-spezifische gene zur diagnose, prognose und behandlung von prostata-krebs
DE68928728T2 (de) Diagnose von retinoblastoma
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
PT948604E (pt) Produtos e metodos relacionados com pyk2
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
ATE312914T1 (de) Rdgb-proteine
CA2201865A1 (en) Laminin chains: diagnostic and therapeutic use
NO930406L (no) Spesifikke antistoffer mot aktiverte blodplater samt fremstilling derav
UA33330A (uk) Спосіб діагностики ендогенної інтоксикації
ATA38797A (de) Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: TRYGGVASON, KARL, STOCKHOLM, SE

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee